In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new data from the VESALIUS-CV trial.
As Healio previously reported, in the main results of VESALIUS-CV, the PCSK9 inhibitor evolocumab (Repatha, Amgen) lowered risk for major adverse CV events by 25% compared with placebo in patients with atherosclerosis or high-risk diabetes and LDL 90 mg/dL or more but no prior MI or stroke. At EuroPCR, Brian A. Bergmark, MD, interventional cardiologist at Brigham

Results published in JAMA Network Open showed certain patient-, care- and structural-level factors may influence time to total hip arthroplasty among patients in the U.S. military who had a diagnosis of hip osteoarthritis.
Brandon L. Hillery, MD, and colleagues retrospectively reviewed data from 37,239 patients (58% men; 63% white, 22% Black, 5% Hispanic, 4% Asian and Pacific Islander) seen at U.S. military and civilian health care facilities and diagnosed with hip OA between March 1, 2018, to March 30, 2023, who received at least one additional visit 1 week to 3 years after the index date.

Healio has partnered with the Nurse Practitioner Associates for Continuing Education, or NPACE, to integrate its Healio AI tool into NPACE’s in-person and on-demand CME.
“NPACE is excited to further our collaboration with Healio and the new Healio AI tool,” NPACE Chief Operating Officer Josh Plotkin said in a press release. “AI is quickly ascending to the forefront of being used by advanced practice providers. Healio’s AI tool, being predicated on medical research, studies and professional insights, will enhance professional development and learning across NPACE

CHICAGO — Patients with Alzheimer’s disease on amyloid-targeting therapy had less cognitive decline when their baseline amyloid burden was lower, according to a poster presented at the American Academy of Neurology Annual Meeting.
“This is a dataset of people who had at least 6 months of treatment with the donanemab or 12 months of treatment with the lecanemab,” Ahlanna Olson, clinical research coordinator, department of clinical neurology, Weill Cornell Medicine, told Healio.
Olson and colleagues conducted a study with a cohort that included 64 patients receiving

CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the research pipeline, driven by both dermatologic and rheumatologic advancements, according to a speaker.
Although there has not been a single approved drug for cutaneous lupus in 75 years, researchers are hopeful that emerging treatments will soon be available for patients, Benjamin Chong, MD, professor of dermatology at the University of Texas Southwestern Medical Center, said during a presentation at Cleveland Clinic’s Medical Dermatology Therapy Update IV.
“The

Most health care professionals in the U.S. said they would consider prescribing combination levothyroxine and liothyronine therapy for euthyroid adults with hypothyroidism symptoms, according to study data.
In a report published in AACE Endocrinology and Diabetes, researchers received survey responses from 299 American Association of Clinical Endocrinology members in the U.S. who reported treating hypothyroidism. All the respondents stated that levothyroxine was the first-line therapy for patients with hypothyroidism. However, the survey revealed differences with approaches to patient

Alcohol can greatly damage health and is tied to over dozens of diseases, but some harms ae possibly reversible with reduced or no drinking, a new report in Addiction indicates.
“The main message is one we expected, and our review confirms it: alcohol is a major contributor to many diseases, injuries, and early death,” study authors Sinclair Carr, a PhD candidate at Harvard T.H. Chan School of Public Health, and Jürgen T. Rehm, PhD, senior scientist at the Canadian Center for Addiction and Mental Health, told Healio.
“Whether to drink, and how much, is ultimately the individual’s decision,”

CHICAGO — A remote weight-loss intervention significantly improved multiple quality of life metrics for women with breast cancer and obesity, including physical function.
Data from the Breast Cancer Weight Loss (BWEL) trial, presented at ASCO Annual Meeting, showed participants randomly assigned to the telephone-based program also had significantly better physical and mental health, as well as social functioning, compared with those who received standard care alone. Benefits persisted for 2 years.
“This program made a really concrete difference in people’s lives,” Jennifer A. Ligibel, MD,

ORLANDO — Among adults with obstructive sleep apnea who do not meet the CMS requirement for CPAP coverage, 36% used CPAP at 12 months, according to data presented at the American Thoracic Society International Conference.
Notably, CMS only covers CPAP for patients with OSA if they use it for at least 4 hours on 70% of nights during a 30-day window within the first 90 days, according to researchers.
“Clinicians should continue supporting patients who are motivated to use CPAP, including making additional efforts to help patients qualify for ongoing coverage even if they do not meet the 90-day

Across three early cow’s milk formula exposure groups vs. no exposure, none were significantly linked to the odds for cow’s milk allergy or sensitization at 1 year, according to study findings.
“There was no clear evidence of an association between very early transient exposure and the risk of any cow’s milk allergy outcomes at age 1 or 6 years,” Erin Pitt, PhD, postdoctoral research fellow at the Child Health Research Centre, University of Queensland, and colleagues wrote in The Journal of Allergy and Clinical Immunology: In Practice.
“Given the higher prevalence of milk sensitization for this